GSK statement on dismissal of Paxil product liability trial in Philadelphia Court of Common pleas

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

GSK statement on dismissal of Paxil product liability trial in Philadelphia Court of Common pleas  



http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10100.htm

Issued: November 22, 2010, Philadelphia, PA



On November 22, 2010, a Philadelphia judge entered judgment in favor of GSK and dismissed a case alleging that use of Paxil during pregnancy caused 14-year-old Anna Blyth to be born with certain cardiac birth defects.



GSK is gratified by Judge Glazer's dismissal of the case.



Unfortunately, birth defects occur in three to five percent of all live births, whether or not the mother was taking medication during pregnancy.



GSK believes it acted properly and responsibly in researching and studying Paxil, including sharing documentation and submitting results from studies on Paxil to regulators. We also believe that once approved for use, the company acted properly in marketing the medicine, including monitoring its safety, updating pregnancy information in the medicine's labeling as new information became available and communicating important safety information to regulatory agencies, the scientific and medical community and the public.



GSK will continue to vigorously defend this litigation and will try cases where appropriate.



GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information go to us.gsk.com, follow us on twitter.com/GSKUS or visit our blog (www.morethanmedicine.us.gsk.com/blog/).